{"id":"NCT00396318","sponsor":"Genentech, Inc.","briefTitle":"A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters","officialTitle":"A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-06","completion":null,"firstPosted":"2006-11-06","resultsPosted":"2011-04-27","lastUpdate":"2011-04-27"},"enrollment":251,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dysfunctional Central Venous Access Catheters"],"interventions":[{"type":"DRUG","name":"tenecteplase","otherNames":[]}],"arms":[{"label":"Tenecteplase","type":"EXPERIMENTAL"}],"summary":"This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study and treated with one or two doses of tenecteplase.","primaryOutcome":{"measure":"Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase","timeFrame":"120 minutes after first dose","effectByArm":[{"arm":"Tenecteplase","deltaMin":72,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":246},"commonTop":["Pyrexia","Neutropenia","Nausea","Febrile Neutropenia","Conjunctivitis"]}}